Authors:
KLIJN J
HAMILTON A
BEEX L
MAURIAC L
PARIDAENS R
ROY JA
AWADA A
VANVRECKEM A
PALMER P
PICCART M
Citation: J. Klijn et al., EORTC-10941 - FINAL RESULTS OF A PHASE-II STUDY OF LIAROZOLE FUMARATEIN PATIENTS WITH METASTATIC BREAST-CANCER, European journal of cancer, 34, 1998, pp. 72-72
Authors:
PARIDAENS R
ROY JA
NOOIJ M
KLIJN J
HOUSTON SJ
BEEX LVAM
VINHOLES J
TOMIAK E
VANVRECKEM A
LANGENAEKEN C
VANGLABBEKE M
PICCART MJ
Citation: R. Paridaens et al., VOROZOLE (RIVIZOR(TM)) - AN ACTIVE AND WELL TOLERATED NEW AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER PATIENTS WITH PRIOR TAMOXIFEN EXPOSURE, Anti-cancer drugs, 9(1), 1998, pp. 29-35
Citation: I. Adriaenssen et al., RESOURCE IMPLICATIONS OF PACLITAXEL CISPLATINUM VERSUS CYCLOPHOSPHAMIDE/CISPLATINUM IN THE TREATMENT OF ADVANCED OVARIAN-CANCER/, European journal of cancer, 33, 1997, pp. 1-1
Authors:
AWADA A
VANVRECKEM A
PARIDAENS R
BRUNING PF
KLIJN J
TOMIAK E
VINHOLES J
ROY JA
KUSENDA Z
BOES GH
VANGLABBEKE M
PICCART MJ
Citation: A. Awada et al., EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 5 YEARSOF EUROPEAN COLLABORATION IN NEW DRUG DEVELOPMENT FOR BREAST-CANCER, European journal of cancer, 33(8), 1997, pp. 1173-1176
Authors:
BERTELSEN K
KAERN J
SIMONSEN E
PICCART MJ
BOES GH
TIMMERS P
ROY JA
PECCORELLI S
STUART NCICG
JAMES K
CASSIDY J
KAYE S
Citation: K. Bertelsen et al., IS CISPLATIN-TAXOL (PT) THE STANDARD TREATMENT IN ADVANCED OVARIAN-CANCER - THE NOCOVA, European journal of cancer, 33, 1997, pp. 614-614
Authors:
DEVALERIOLA D
AWADA A
ROY JA
DILEO A
BIGANZOLI L
PICCART M
Citation: D. Devaleriola et al., BREAST-CANCER THERAPIES IN DEVELOPMENT - A REVIEW OF THEIR PHARMACOLOGY AND CLINICAL POTENTIAL, Drugs, 54(3), 1997, pp. 385-413
Citation: Ja. Roy et al., HORMONE REPLACEMENT THERAPY IN WOMEN WITH BREAST-CANCER - DO THE RISKS OUTWEIGH THE BENEFITS, Journal of clinical oncology, 14(3), 1996, pp. 997-1006
Authors:
PICCARTGEBHART MJ
BRUNING P
GAMUCCI T
KLIJN J
ROY JA
AWADA A
KUSENDA Z
VANVRECKEM A
PARIDAENS R
Citation: Mj. Piccartgebhart et al., AN ONGOING EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCERCROSSOVER TRIAL COMPARING SINGLE-AGENT PACLITAXEL AND DOXORUBICIN AS FIRST-LINE AND SECOND-LINE TREATMENT OF ADVANCED BREAST-CANCER, Seminars in oncology, 23(5), 1996, pp. 11-15
Authors:
PARIDAENS R
BRUNING P
CALABRESI F
AWADA A
ROY JA
KUSENDA Z
PICCART M
Citation: R. Paridaens et al., TAXOL OR DOXORUBICIN AS FIRST LINE CHEMOTHERAPY IN ADVANCED BREAST-CANCER (ABC) - A PROSPECTIVE RANDOMIZED PHASE-II STUDY WITH CROSSOVER, European journal of cancer, 31A, 1995, pp. 346-346
Citation: Ja. Roy et al., REGARDING THE DILEMMA OF ADJUVANT THERAPY IN POSTMENOPAUSAL PATIENTS WITH NODE-POSITIVE, ESTROGEN RECEPTOR-POSITIVE BREAST-CANCER - ARE WE BETTER INFORMED, Journal of clinical oncology, 13(4), 1995, pp. 1044-1044
Authors:
ZOU H
HOOD GM
ROY JA
SCHULTZ RJ
JACKMAN JA
Citation: H. Zou et al., HF DIFFUSION IN DILUTE FE-FREE ZR(NB) ALLOYS, Philosophical magazine. A. Physics of condensed matter. Defects and mechanical properties, 71(4), 1995, pp. 901-906
Authors:
ZOU H
HOOD GM
NAKAJIMA H
ROY JA
SCHULTZ RJ
Citation: H. Zou et al., THE SOLID SOLUBILITY OF NI AND CO IN ALPHA-ZR - A SECONDARY-ION MASS-SPECTROMETRY STUDY, Journal of nuclear materials, 223(2), 1995, pp. 186-188
Citation: H. Zou et al., FORMATION AND STABILITY OF FE-RICH PRECIPITATES IN DILUTE ZR(FE) SINGLE-CRYSTAL ALLOYS, Metallurgical and materials transactions. A, Physical metallurgy andmaterials science, 25(7), 1994, pp. 1359-1365
Authors:
ZOU H
HOOD GM
ROY JA
SCHULTZ RJ
JACKMAN JA
Citation: H. Zou et al., THE SOLID SOLUBILITY OF FE IN ALPHA-ZR - A SECONDARY-ION MASS-SPECTROMETRY STUDY, Journal of nuclear materials, 210(3), 1994, pp. 239-243